NASDAQ:FTSV - Forty Seven Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.48 +0.06 (+0.39 %)
(As of 02/17/2019 10:34 AM ET)
Previous Close$15.48
Today's Range$14.7948 - $15.72
52-Week Range$12.02 - $23.83
Volume139,969 shs
Average Volume149,541 shs
Market Capitalization$480.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
Phone650-352-4150

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees46
Market Cap$480.89 million
OptionableNot Optionable

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) released its earnings results on Tuesday, November, 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.17. View Forty Seven's Earnings History.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Forty Seven.

What price target have analysts set for FTSV?

7 brokers have issued twelve-month price objectives for Forty Seven's shares. Their forecasts range from $21.00 to $36.00. On average, they anticipate Forty Seven's share price to reach $27.7143 in the next twelve months. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Forty Seven.

What is the consensus analysts' recommendation for Forty Seven?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (2/12/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating on FTSV and our 12-month price target of $21.00 per share. We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and 3% terminal growth rate. We derive rNPV of $975M for 5F9 and add in cash, cash equivalents, and short-term investments of $154M to arrive at a 12-month price target of $20.79 per diluted share, which we round to $21.00." (1/14/2019)

Has Forty Seven been receiving favorable news coverage?

News headlines about FTSV stock have been trending negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Forty Seven earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Forty Seven's key competitors?

Who are Forty Seven's key executives?

Forty Seven's management team includes the folowing people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

When did the company's lock-up period expire?

Forty Seven's lock-up period expired on Tuesday, December 25th. Forty Seven had issued 7,035,000 shares in its public offering on June 28th. The total size of the offering was $112,560,000 based on an initial share price of $16.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Forty Seven's major shareholders?

Forty Seven's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.72%), Bourgeon Capital Management LLC (1.40%), Massachusetts Financial Services Co. MA (1.02%), Northern Trust Corp (0.29%), Geode Capital Management LLC (0.28%) and United Services Automobile Association (0.23%). Company insiders that own Forty Seven stock include Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Lifesciences Iii LP Clarus, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View Institutional Ownership Trends for Forty Seven.

Which major investors are selling Forty Seven stock?

FTSV stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, United Services Automobile Association, Raymond James & Associates and Millennium Management LLC. Company insiders that have sold Forty Seven company stock in the last year include Chris H Takimoto, Irving Weissman, Mark Anthony Mccamish and Ravindra Majeti. View Insider Buying and Selling for Forty Seven.

Which major investors are buying Forty Seven stock?

FTSV stock was acquired by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC, BlackRock Inc., Northern Trust Corp, Geode Capital Management LLC, Exane Asset Management, Candriam Luxembourg S.C.A., Bank of New York Mellon Corp and Virtu Financial LLC. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Lifesciences Iii LP Clarus, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Insider Buying and Selling for Forty Seven.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $15.48.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $480.89 million. Forty Seven employs 46 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Featured Article: Put Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel